Loading organizations...
§ Public · Cambridge, MA, USA
Biotechnology and pharmaceutical clinically differentiated medicines for oncology & immune-inflammatory diseases. Clinical-stage drugs.
Founded in January 2020 and led by CEO Melanie Nallicheri, EQRx is a Cambridge, Massachusetts pharmaceutical company developing clinically differentiated medicines for oncology and immune inflammatory diseases. The biotechnology firm went public in late 2021 through a merger with the special purpose acquisition company CM Life Sciences III, achieving an initial valuation near $4.2 billion. Backed by investors including Arboretum Ventures and Corvex Management LP, the company initially pursued a strategy of delivering radically lower priced therapeutics before pivoting its business model. Following FDA regulatory setbacks regarding its Chinese drug candidates, the organization abandoned its low cost model in 2023 to prioritize its clinical stage assets like lerociclib. This strategic reset included workforce reductions designed to save $125 million annually, leaving the firm with a $1.3 billion cash position by the first quarter of 2023.
EQRx has raised $700.0M across 2 funding rounds.
EQRx has raised $700.0M in total across 2 funding rounds.
EQRx is a biotechnology company founded in 2019 in Cambridge, Massachusetts, focused on developing innovative medicines for high-cost diseases like cancer and inflammatory conditions, initially aiming to deliver them at radically lower prices through efficient processes.[1][2][3][5] It built a pipeline of over 10 programs, including late-stage oncology assets like aumolertinib and sugemalimab, while leveraging data science, tech integration, and partnerships to accelerate development.[2][3] The company raised $700M+ and went public via a SPAC merger valued at $1.8B, but faced setbacks, abandoning its low-price model, dropping key candidates, and undergoing major layoffs before its acquisition by Revolution Medicines in November 2023.[1][4]
EQRx targeted patients and payers in oncology and metabolic diseases, solving high drug costs and slow development by re-engineering the pharma process—focusing on validated biology, fast trials (initially in China), and end-to-end tech.[2][3] Growth peaked with VC backing from Andreessen Horowitz and Bain, but momentum stalled amid regulatory hurdles, strategy shifts, and market pressures, leading to its pivot and sale at the P2P stage.[1][4]
EQRx was co-founded in 2019 by Alexis Borisy, a serial biotech entrepreneur and investor, and Melanie Nallicheri, a biotech executive, with a mission to "remake medicine" by disrupting inefficient pharma R&D and pricing.[2][3] Borisy's track record in life sciences ventures and Nallicheri's operational expertise drove the vision for a tech-infused model to launch medicines faster and cheaper, inspired by Amazon-like process overhauls.[2] Early traction came from massive funding—over $1B in 2020-2021—including from a16z and a $1.8B SPAC with CM Life Sciences III in 2021, enabling rapid pipeline buildup.[2][3]
Pivotal moments included partnerships with Exscientia and AbCellera for drug discovery, and Phase 3 data on Chinese-sourced oncology drugs, but regulatory issues (e.g., FDA concerns on China trials) and external factors like the Inflation Reduction Act forced abandonment of the low-price strategy by 2023, culminating in layoffs and acquisition by Revolution Medicines.[1][4]
EQRx stood out in biotech through these key elements:
These aimed for Amazon-style efficiency but proved challenging amid regulatory and market realities.[2][4]
EQRx rode the biotech-tech convergence trend, applying AI/data science to pharma R&D amid rising drug costs and demands for affordability, aligning with payer pressures and value-based care.[2][3] Timing was ideal post-2019 with VC boom enabling $1B+ raises, but faltered on China trial risks (exposed by Lilly's FDA issues) and U.S. policies like the Inflation Reduction Act's pricing controls.[4] It highlighted market forces favoring efficient, tech-driven biopharma but punishing unproven disruptions—showing how execution trumps ambition in a sector with high failure rates.[4]
EQRx influenced the ecosystem by pioneering "next-gen" models, inspiring tech-biotech hybrids, though its unwind underscored barriers for outsiders challenging Big Pharma incumbents.[2][4]
Post-acquisition by Revolution Medicines in 2023, EQRx's independent story ends, with assets like its remaining CDK4/6 candidate (lerociclib) absorbed into a stronger platform amid a crowded field.[1][4] Trends like AI-accelerated discovery and pricing reforms will shape survivors, but EQRx's arc warns of overhyping process revolutions without regulatory alignment. Its legacy may evolve through Revolution Medicines advancing integrated pipelines, tying back to the original vision of efficient, patient-focused biotech—now tempered by real-world pharma dynamics.[1][4]
EQRx has raised $700.0M in total across 2 funding rounds.
EQRx's investors include Andreessen Horowitz, Arboretum Ventures, ARCH Venture Partners, Casdin Capital, Krishna Yeshwant, Nextech, Section 32.
EQRx has raised $700.0M across 2 funding rounds. Most recently, it raised $500.0M Series B in January 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 11, 2021 | $500M Series B | — | — | Announced |
| Jan 12, 2020 | $200M Series A | Andreessen Horowitz, Arboretum Ventures, ARCH Venture Partners, Casdin Capital, Krishna Yeshwant, Nextech, Section 32 | — | Announced |